Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 500
Cost of revenue	585
Gross profit (loss)	(85)
Operating expenses:
Sales and marketing	8,895	2,789
General and administrative	25,566	9,599
Research and development	19,847	10,963
Total operating expenses	54,308	23,351
Loss from operations	(54,393)	(23,351)
Other income (expense):
Interest expense		(53)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	1,682	(5,327)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note		(660)
Debt extinguishments loss - Senior Secured Convertible Notes	(3,715)	(6,497)
Debt forgiveness	300
Other income (expense), net	(1,733)	(12,537)
Loss before provision for income tax	(56,126)	(35,888)
Provision for income taxes
Net loss before noncontrolling interests	(56,126)	(35,888)
Net loss attributable to the noncontrolling interests	5,779	1,612
Net loss attributable to PAVmed Inc.	(50,347)	(34,276)
Less: Series B Convertible Preferred Stock dividends earned	(283)	(287)
Net loss attributable to PAVmed Inc. common stockholders	$ (50,630)	$ (34,563)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (0.65)	$ (0.72)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted	$ (0.65)	$ (0.73)
Weighted average common shares outstanding, basic and diluted	77,515,767	47,432,115